Highly sensitive C-reactive protein and male gender are independently related to the severity of coronary disease in patients with metabolic syndrome and an acute coronary event

Brazilian Journal of Medical and Biological Research

Volumn 43, Issue 3, 2010, Pages 297-302

  Monteiro, C M C ^a   Pinheiro, L F ^a   Izar, M C ^a   Barros, S W ^a   Vasco, M B ^a   Fischer, S M ^a   Povoa, R M ^a   Brandao S A ^a   Santos, A O ^a   Oliveira, L ^a   Carvalho, A C ^a   Fonseca, F A H ^a  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Acute coronary syndrome; C reactive protein; Gender; Gensini score; Metabolic syndrome

Indexed keywords

C REACTIVE PROTEIN; HIGHLY SENSITIVE C REACTIVE PROTEIN; UNCLASSIFIED DRUG;

ACUTE HEART INFARCTION; ADULT; AGED; ANGIOCARDIOGRAPHY; ARTERIAL WALL THICKNESS; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY DISEASE; CORONARY RISK; DISEASE ASSOCIATION; DISEASE SEVERITY; FEMALE; HIGH RISK POPULATION; HUMAN; MALE; METABOLIC SYNDROME X; SEX DIFFERENCE; UNSTABLE ANGINA PECTORIS;

ANGINA;

EID: 77950161785     PISSN: 0100879X     EISSN: 1414431X     Source Type: Journal    
DOI: 10.1590/S0100-879X2010005000008     Document Type: Article

References (34)

1. Lakka HM, Laaksonen DE, Lakka TA, Niskanen LK, Kumpusalo E, Tuomilehto J, et al. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA 2002; 288: 2709-2716.
2. Lamarche B, Lemieux I, Despres JP. The small, dense LDL phenotype and the risk of coronary heart disease: epidemiology, patho-physiology and therapeutic aspects. Diabetes Metab 1999; 25: 199-211.
3. Feinberg MS, Schwartz R, Tanne D, Fisman EZ, Hod H, Zahger D, et al. Impact of the metabolic syndrome on the clinical outcomes of non-clinically diagnosed diabetic patients with acute coronary syndrome. Am J Cardiol 2007; 99: 667-672.
4. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001; 285: 2486-2497.
5. Rutter MK, Meigs JB, Sullivan LM, D'Agostino RB Sr, Wilson PW. C-reactive protein, the metabolic syndrome, and prediction of cardiovascular events in the Framingham Offspring Study. Circulation 2004; 110: 380-385.
6. Cao JJ, Arnold AM, Manolio TA, Polak JF, Psaty BM, Hirsch CH, et al. Association of carotid artery intima-media thick ness, plaques, and C-reactive protein with future cardiovascular disease and all-cause mortality: the Cardiovascular Health Study. Circulation 2007; 116: 32-38.
7. Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM Jr, Kastelein JJ, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008; 359: 2195-2207.
8. Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM Jr, Kastelein JJ, et al. Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial. Lancet 2009; 373: 1175-1182.
9. Glynn RJ, Danielson E, Fonseca FA, Genest J, Gotto AM Jr, Kastelein JJ, et al. A randomized trial of rosuvastatin in the prevention of venous thromboembolism. N Engl J Med 2009; 360: 1851-1861.
10. Ridker PM, Fonseca FA, Genest J, Gotto AM, Kastelein JJ, Khurmi NS, et al. Baseline characteristics of participants in the JUPITER trial, a randomized placebo-controlled primary prevention trial of statin therapy among individuals with low low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein. Am J Cardiol 2007; 100: 1659-1664.
11. McNeill AM, Rosamond WD, Girman CJ, Golden SH, Schmidt MI, East HE, et al. The metabolic syndrome and 11-year risk of incident cardiovascular disease in the atherosclerosis risk in communities study. Diabetes Care 2005; 28: 385-390.
12. Hunt KJ, Resendez RG, Williams K, Haffner SM, Stern MP. National Cholesterol Education Program versus World Health Organization metabolic syndrome in relation to allcause and cardiovascular mortality in the San Antonio Heart Study. Circulation 2004; 110: 1251-1257.
13. Ridker PM, Wilson PW, Grundy SM. Should C-reactive protein be added to metabolic syndrome and to assessment of global cardiovascular risk? Circulation 2004; 109: 2818-2825.
14. Yavuz B, Kabakci G, Aksoy H, Tulumen E, Deveci OS, Aytemir K, et al. Determining the relationship between metabolic syndrome score and angiographic severity of coronary artery disease. Int J Clin Pract 2008; 62: 717-722.
15. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972; 18: 499-502.
16. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 412-419.
17. Gensini GG. A more meaningful scoring system for determining the severity of coronary heart disease. Am J Cardiol 1983; 51: 606.
18. Skilton MR, Moulin P, Serusclat A, Nony P, Bonnet F. A comparison of the NCEP-ATPIII, IDF and AHA/NHLBI metabolic syndrome definitions with relation to early carotid atherosclerosis in subjects with hypercholesterolemia or at risk of CVD: evidence for sex-specific differences. Atherosclerosis 2007; 190: 416-422.
19. Faulx MD, Wright AT, Hoit BD. Detection of endothelial dysfunction with brachial artery ultrasound scanning. Am Heart J 2003; 145: 943-951.
20. Isomaa B, Almgren P, Tuomi T, Forsen B, Lahti K, Nissen M, et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 2001; 24: 683-689.
21. Bonora E, Kiechl S, Willeit J, Oberhollenzer F, Egger G, Bonadonna RC, et al. Carotid atherosclerosis and coronary heart disease in the metabolic syndrome: prospective data from the Bruneck study. Diabetes Care 2003; 26: 1251-1257.
22. Ford ES. The metabolic syndrome and mortality from cardiovascular disease and all-causes: findings from the National Health and Nutrition Examination Survey II Mortality Study. Atherosclerosis 2004; 173: 309-314.
23. Bertoni AG, Wong ND, Shea S, Ma S, Liu K, Preethi S, et al. Insulin resistance, metabolic syndrome, and subclinical atherosclerosis: the Multi-Ethnic Study of Atherosclerosis (MESA). Diabetes Care 2007; 30: 2951-2956.
24. Hunt KJ, Williams K, Hazuda HP, Stern MP, Haffner SM. The metabolic syndrome and the impact of diabetes on coronary heart disease mortality in women and men: the San Antonio Heart Study. Ann Epidemiol 2007; 17: 870-877.
25. Deedwania P, Barter P, Carmena R, Fruchart JC, Grundy SM, Haffner S, et al. Reduction of low-density lipoprotein cholesterol in patients with coronary heart disease and metabolic syndrome: analysis of the Treating to New Targets study. Lancet 2006; 368: 919-928.
26. Zanchetti A, Hennig M, Baurecht H, Tang R, Cuspidi C, Carugo S, et al. Prevalence and incidence of the metabolic syndrome in the European Lacidipine Study on Atherosclerosis (ELSA) and its relation with carotid intima-media thickness. J Hypertens 2007; 25: 2463-2470.
27. Fan AZ. Metabolic syndrome and progression of atherosclerosis among middle-aged US adults. J Atheroscler Thromb 2006; 13: 46-54.
28. Kasai T, Miyauchi K, Kubota N, Tamura H, Kojima T, Yokoyama K, et al. The relationship between the metabolic syndrome defined by various criteria and the extent of coronary artery disease. Atherosclerosis 2008; 197: 944-950.
29. Kronmal RA, McClelland RL, Detrano R, Shea S, Lima JA, Cushman M, et al. Risk factors for the progression of coronary artery calcification in asymptomatic subjects: results from the Multi-Ethnic Study of Atherosclerosis (MESA). Circulation 2007; 115: 2722-2730.
30. Duarte ER, Pellanda LC, Portal VL. [Inflammatory, lipid, and metabolic profile in acute ischemic syndrome: correlation with hospital and posthospital events]. Arq Bras Cardiol 2005; 84: 122-129.
31. Monteiro CM, Oliveira L, Izar MC, Helfenstein T, Santos AO, Fischer SM, et al. Early glucometabolic profile in patients with acute coronary syndromes and metabolic syndrome. Arq Bras Cardiol 2009; 92: 89-99.
32. Yusuf S, Hawken S, Ounpuu S, Dans T, Avezum A, Lanas F, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART Study): case-control study. Lancet 2004; 364: 937-952.
33. Moreira GC, Cipullo JP, Martin JF, Ciorlia LA, Godoy MR, Cesarino CB, et al. Evaluation of the awareness, control and cost-effectiveness of hypertension treatment in a Brazilian city: populational study. J Hypertens 2009; 27: 1900-1907.
34. Liu Y, Li X, Peng D, Tan Z, Liu H, Qing Y, et al. Usefulness of serum cathepsin L as an independent biomarker in patients with coronary heart disease. Am J Cardiol 2009; 103: 476-481.